<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <ref-type name="Journal Article">17</ref-type>
  <contributors>
    <authors>
      <author>Zhao, Jingyi</author>
      <author>DiGiacomo, Vincent</author>
      <author>Ferreras-Gutierrez, Mariola</author>
      <author>Dastjerdi, Shiva</author>
      <author>Ibanez de Opakua, Alain</author>
      <author>Park, Jong-Chan</author>
      <author>Luebbers, Alex</author>
      <author>Chen, Qingyan</author>
      <author>Beeler, Aaron</author>
      <author>Blanco, Francisco J</author>
      <author>Garcia-Marcos, Mikel</author>
    </authors>
    <subsidiary-authors>
      <author>AG Zweckstetter</author>
    </subsidiary-authors>
  </contributors>
  <titles>
    <title>Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer.</title>
    <secondary-title>Proceedings of the National Academy of Sciences of the United States of America</secondary-title>
  </titles>
  <periodical>
    <full-title>Proceedings of the National Academy of Sciences of the United States of America</full-title>
  </periodical>
  <publisher>National Acad. of Sciences</publisher>
  <pub-location>Washington, DC</pub-location>
  <isbn>0027-8424</isbn>
  <electronic-resource-num>10.1073/pnas.2213140120</electronic-resource-num>
  <language>English</language>
  <pages>e2213140120</pages>
  <number>18</number>
  <volume>120</volume>
  <abstract>Activation of heterotrimeric G-proteins (Gαβγ) by G-protein-coupled receptors (GPCRs) is a quintessential mechanism of cell signaling widely targeted by clinically approved drugs. However, it has become evident that heterotrimeric G-proteins can also be activated via GPCR-independent mechanisms that remain untapped as pharmacological targets. GIV/Girdin has emerged as a prototypical non-GPCR activator of G proteins that promotes cancer metastasis. Here, we introduce IGGi-11, a first-in-class small-molecule inhibitor of noncanonical activation of heterotrimeric G-protein signaling. IGGi-11 binding to G-protein α-subunits (Gαi) specifically disrupted their engagement with GIV/Girdin, thereby blocking noncanonical G-protein signaling in tumor cells and inhibiting proinvasive traits of metastatic cancer cells. In contrast, IGGi-11 did not interfere with canonical G-protein signaling mechanisms triggered by GPCRs. By revealing that small molecules can selectively disable noncanonical mechanisms of G-protein activation dysregulated in disease, these findings warrant the exploration of therapeutic modalities in G-protein signaling that go beyond targeting GPCRs.</abstract>
  <notes/>
  <label>PUB:(DE-HGF)16, ; 0, ; </label>
  <keywords>
    <keyword>Vesicular Transport Proteins: metabolism</keyword>
    <keyword>Microfilament Proteins: metabolism</keyword>
    <keyword>Signal Transduction</keyword>
    <keyword>Receptors, G-Protein-Coupled: metabolism</keyword>
    <keyword>Heterotrimeric GTP-Binding Proteins: metabolism</keyword>
    <keyword>Neoplasms: metabolism</keyword>
    <keyword>G protein</keyword>
    <keyword>GPCR</keyword>
    <keyword>cancer</keyword>
    <keyword>drug discovery</keyword>
    <keyword>Vesicular Transport Proteins</keyword>
    <keyword>Microfilament Proteins</keyword>
    <keyword>Receptors, G-Protein-Coupled</keyword>
    <keyword>Heterotrimeric GTP-Binding Proteins</keyword>
  </keywords>
  <accession-num/>
  <work-type>Journal Article</work-type>
  <dates>
    <pub-dates>
      <year>2023</year>
    </pub-dates>
  </dates>
  <accession-num>DZNE-2023-00494</accession-num>
  <year>2023</year>
  <custom2>pmc:PMC10160980</custom2>
  <custom6>pmid:37098067</custom6>
  <urls>
    <related-urls>
      <url>https://pub.dzne.de/record/257779</url>
      <url>https://doi.org/10.1073/pnas.2213140120</url>
    </related-urls>
  </urls>
</record>

</records>
</xml>